Abstract 1575P
Background
Exposure to secondhand smoke (SHS) can elevate the overall cancer risk for individuals who have never smoked. Smoke-free policies aim to protect non-smokers from the harmful effects of SHS and align with the guidelines set forth by the World Health Organization (WHO) Framework Convention on Tobacco Control. However, restrictions on smoking in outdoor public places are limited.
Methods
Between 2021 and 2024, the Spanish Association Against Cancer (SAAC) launched a program to enhance smoking prohibitions in outdoor areas. To do so, we first identified public places highly visited by smokers and vulnerable populations. Collaboration agreements were established with city halls, public organizations, and institutions interested in the project. These agreements involved advertising prohibiting smoking and vaping, smoke-free events, and training programs for the personnel responsible for enforcing these recommendations.
Results
Since the program's implementation, 358 collaboration agreements have been signed with 235 city halls through the 52 provinces of Spain. Most agreements (n=129, 36%) were launched to free urban and rural parks and green places from SHS. Other included outdoor sports centers and sports grounds (n=78,22%), universities (n=40,11%), and beaches (n=10, 3%). As a result of the good population and city halls' response to the initiative, the SAAC enforced the inclusion and regulation of outdoor smoke-free places in the new national comprehensive plan for the prevention of smoking.
Conclusions
Population-level initiatives to enforce smoke-free policies in outdoor places can result in new national legislation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Spanish Association Against Cancer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10